RG7795

RG7795

Clinical data
Other names	RG-7795; ANA773; ANA-773
Legal status
Legal status	Investigational
Identifiers
CAS Number	892498-64-5  Y
PubChem CID	11587892
DrugBank	DB06329
ChemSpider	9762656
UNII	QTI86134YL
Chemical and physical data
Formula	C12H14N4O5S
Molar mass	326.33 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1N(C=2C(S1)=CN=C(N)N2)[C@]3([C@H](OC(C)=O)C[C@@H](CO)O3)[H]
InChI InChI=1S/C12H14N4O5S/c1-5(18)20-7-2-6(4-17)21-10(7)16-9-8(22-12(16)19)3-14-11(13)15-9/h3,6-7,10,17H,2,4H2,1H3,(H2,13,14,15)/t6-,7+,10+/m0/s1 Key:HOOMGTNENMZAFP-NYNCVSEMSA-N

RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. ^[1] It is an orally-available prodrug of isatoribine, ^[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011. ^[3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity. ^[2]

Chemical structure of isatoribine

As of 2021, development of RG7795 appears to be discontinued. ^[4]

References

1. "RG 7795". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 August 2017.
2. Funk E, Kottilil S, Gilliam B, Talwani R (May 2014). "Tickling the TLR7 to cure viral hepatitis". Journal of Translational Medicine. 12: 129. doi: 10.1186/1479-5876-12-129 . PMC   4039542 . PMID   24884741.
3. "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, 2016.
4. Sachin Bhagchandani, Jeremiah A.Johnson, and Darrell J.Irvine (2021). "Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants". Advanced Drug Delivery Reviews. 175: 113803. doi:10.1016/j.addr.2021.05.013. PMC   9003539 . PMID   34058283.